MicroRNA Analysis in Meningiomas with Different Degrees of Tissue Stiffness: A Potential Tool for Effective Preoperative Planning.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
05
03
2024
accepted:
26
08
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
aheadofprint
Résumé
Meningioma, the most common primary intracranial tumor, presents challenges in surgical treatment because of varying tissue stiffness. This study explores the molecular background of meningioma stiffness, a critical factor in surgical planning and prognosis, focusing on the utility of microRNAs (miRNAs) as diagnostic biomarkers of tissue stiffness. Patients with meningiomas treated surgically at the University Hospital Brno were included in this study. Total RNA, isolated from tumor tissue samples, underwent quality control and small RNA sequencing to analyze miRNA expression. Differentially expressed miRNAs were identified, and their association with tumor stiffness was assessed. This study identified specific miRNAs differentially expressed in meningiomas with different stiffness levels. Key miRNAs, such as miR-31-5p and miR-34b-5p, showed significant upregulation in stiffer meningiomas. These findings were validated using reverse transcription-quantitative polymerase chain reaction, revealing a potential link between miRNA expression and tumor consistency. The expression of miR-31-5p was most notably associated with the stiffness of the tumor tissue (sensitivity = 71% and specificity = 83%). This research highlights the potential of miRNAs as biomarkers for determining meningioma tissue stiffness. Identifying specific miRNAs associated with tumor consistency could improve preoperative planning and patient prognosis. These findings pave the way for further exploration of miRNAs in the clinical assessment of meningiomas.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Meningioma, the most common primary intracranial tumor, presents challenges in surgical treatment because of varying tissue stiffness. This study explores the molecular background of meningioma stiffness, a critical factor in surgical planning and prognosis, focusing on the utility of microRNAs (miRNAs) as diagnostic biomarkers of tissue stiffness.
METHODS
METHODS
Patients with meningiomas treated surgically at the University Hospital Brno were included in this study. Total RNA, isolated from tumor tissue samples, underwent quality control and small RNA sequencing to analyze miRNA expression. Differentially expressed miRNAs were identified, and their association with tumor stiffness was assessed.
RESULTS
RESULTS
This study identified specific miRNAs differentially expressed in meningiomas with different stiffness levels. Key miRNAs, such as miR-31-5p and miR-34b-5p, showed significant upregulation in stiffer meningiomas. These findings were validated using reverse transcription-quantitative polymerase chain reaction, revealing a potential link between miRNA expression and tumor consistency. The expression of miR-31-5p was most notably associated with the stiffness of the tumor tissue (sensitivity = 71% and specificity = 83%).
CONCLUSION
CONCLUSIONS
This research highlights the potential of miRNAs as biomarkers for determining meningioma tissue stiffness. Identifying specific miRNAs associated with tumor consistency could improve preoperative planning and patient prognosis. These findings pave the way for further exploration of miRNAs in the clinical assessment of meningiomas.
Identifiants
pubmed: 39485054
doi: 10.1227/neu.0000000000003222
pii: 00006123-990000000-01413
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerstvo ZdravotnictvÃ- Ceské Republiky
ID : NV19-03-00559
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Congress of Neurological Surgeons.
Références
Holleczek B, Zampella D, Urbschat S, et al. Incidence, mortality and outcome of meningiomas: a population-based study from Germany. Cancer Epidemiol. 2019;62:101562.
Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(Supplement_4):iv1-iv99.
Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol. 2018;14(21):2161-2177.
Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021;9(3):319.
Maggio I, Franceschi E, Tosoni A, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol. 2021;10(2):CNS72.
Ahmeti H, Borzikowsky C, Hollander D, et al. Risks and neurological benefits of meningioma surgery in elderly patients compared to young patients. J Neurooncol. 2021;154(3):335-344.
Murphy MC, Huston J 3rd, Glaser KJ, et al. Preoperative assessment of meningioma stiffness using magnetic resonance elastography. J Neurosurg. 2013;118(3):643-648.
Sauvigny T, Ricklefs FL, Hoffmann L, Schwarz R, Westphal M, Schmidt NO. Features of tumor texture influence surgery and outcome in intracranial meningioma. Neurooncol Adv. 2020;2(1):vdaa113.
Sumkovski R, Micunovic M, Kocevski I, Ilievski B, Petrov I. Surgical treatment of meningiomas - outcome associated with type of resection, recurrence, Karnofsky performance score, mitotic count. Open Access Maced J Med Sci. 2019;7(1):56-64.
Dalan AB, Gulluoglu S, Tuysuz EC, et al. Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: a relationship between PTX3 and miR-29c. BMC Cancer. 2017;17(1):207.
El-Gewely MR, Andreassen M, Walquist M, et al. Differentially expressed MicroRNAs in meningiomas Grades I and II suggest shared biomarkers with malignant tumors. Cancers (Basel). 2016;8(3):31.
Saydam O, Shen Y, Wurdinger T, et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol. 2009;29(21):5923-5940.
Shi L, Jiang D, Sun G, et al. miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neurooncol. 2012;110(2):155-162.
Zhi F, Zhou G, Wang S, et al. A microRNA expression signature predicts meningioma recurrence. Int J Cancer. 2013;132(1):128-136.
Wang M, Deng X, Ying Q, Jin T, Li M, Liang C. MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. Biochem Biophys Res Commun. 2015;460(2):354-361.
Carneiro V, Cirino M, Panepucci R, et al. The role of microRNA 181d as a possible biomarker associated with tumor progression in meningiomas. Cureus. 2021;13(10):e19158.
Li P, Gao Y, Li F, et al. MicroRNA-18a regulates invasive meningiomas via hypoxia-inducible factor-1α. Exp Ther Med. 2015;10(3):1165-1170.
Kopkova A, Sana J, Machackova T, et al. Cerebrospinal fluid microRNA signatures as diagnostic biomarkers in brain tumors. Cancers (Basel). 2019;11(10):1546.
Zhi F, Shao N, Li B, et al. A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Sci Rep. 2016;6:32067.
NextSeq system denature and dilute libraries guide. Accessed 25 August 2018. https://support.illumina.com/downloads/nextseq-500-denaturing-diluting-libraries-15048776.html
Andrews S. FastQC: a quality control tool for high throughput sequence data. Accessed August 25, 2018. http://www.bioinformatics.babraham.ac.uk/projects/fastqc
Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10-12.
Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(Database issue):D140-D144.
Pantano L, Estivill X, Marti E. SeqBuster, a bioinformatic tool for the processing and analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic cells. Nucleic Acids Res. 2010;38(5):e34.
Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047-3048.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
Smith KA, Leever JD, Chamoun RB. Predicting consistency of meningioma by magnetic resonance imaging. J Neurol Surg B Skull Base. 2015;76(3):225-229.
Yao A, Pain M, Balchandani P, Shrivastava RK. Can MRI predict meningioma consistency?: a correlation with tumor pathology and systematic review. Neurosurg Rev. 2018;41(3):745-753.
Zhai Y, Song D, Yang F, et al. Preoperative prediction of meningioma consistency via machine learning-based radiomics. Front Oncol. 2021;11:657288.
Zhao D, Zhao X, Liu T, et al. Genetic alterations in meningiomas of different textures. Gene. 2016;592(1):134-139.
Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2008;10(3):203-211.
Kopkova A, Sana J, Fadrus P, Slaby O. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clin Chem Lab Med. 2018;56(6):869-879.
Pacifici M, Delbue S, Kadri F, Peruzzi F. Cerebrospinal fluid MicroRNA profiling using quantitative real time PCR. J Vis Exp. 2014;83:e51172.
Saugstad JA, Lusardi TA, Van Keuren-Jensen KR, et al. Analysis of extracellular RNA in cerebrospinal fluid. J Extracell Vesicles. 2017;6(1):1317577.
Slavik H, Balik V, Vrbkova J, et al. Identification of meningioma patients at high risk of tumor recurrence using microRNA profiling. Neurosurgery. 2020;87(5):1055-1063.
Wang L, Chen S, Liu Y, et al. The biological and diagnostic roles of MicroRNAs in meningiomas. Rev Neurosci. 2020;31(7):771-778.
Marigliano C, Badia S, Bellini D, et al. Radiogenomics in clear cell renal cell carcinoma: correlations between advanced CT imaging (texture analysis) and microRNAs expression. Technol Cancer Res Treat. 2019;18:1533033819878458.
Li B, Liu J, Xin X, et al. MiR-34c promotes hepatic stellate cell activation and Liver Fibrogenesis by suppressing ACSL1 expression. Int J Med Sci. 2021;18(3):615-625.
Li F, Ma N, Zhao R, et al. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. J Cell Mol Med. 2014;18(6):966-974.
Ma J, Liu Q, Chen M, et al. MicroRNA-34b-5p binds enhancer of zeste 2 to inhibit milk fat globule-EGF factor 8 expression, affecting liver fibrosis. J Physiol Biochem. 2022;78(4):885-895.
Morizane R, Fujii S, Monkawa T, et al. miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction. Sci Rep. 2014;4:4578.
Niture S, Gadi S, Qi Q, et al. MicroRNA-483-5p inhibits hepatocellular carcinoma cell proliferation, cell steatosis, and fibrosis by targeting PPARα and TIMP2. Cancers (Basel). 2023;15(6):1715.
Piccolo P, Ferriero R, Barbato A, et al. Up-regulation of miR-34b/c by JNK and FOXO3 protects from liver fibrosis. Proc Natl Acad Sci U S A. 2021;118(10):e2025242118.
Bai X, Zheng L, Xu Y, Liang Y, Li D. Role of microRNA-34b-5p in cancer and injury: how does it work? Cancer Cell Int. 2022;22(1):381.
Kim JS, Kim EJ, Lee S, et al. MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas. Exp Mol Med. 2019;51(1):1-10.
Wang N, Li Y, Zhou J. miR-31 functions as an oncomir which promotes epithelial-mesenchymal transition via regulating BAP1 in cervical cancer. Biomed Res Int. 2017;2017:6361420.
Yang J, Liu X, Sun Y, et al. ING5 overexpression upregulates miR-34c-5p/Snail1 to inhibit EMT and invasion of lung cancer cells. Acta Biochim Biophys Sin (Shanghai). 2023;55(5):809-817.
Yu T, Ma P, Wu D, Shu Y, Gao W. Functions and mechanisms of microRNA-31 in human cancers. Biomed Pharmacother. 2018;108:1162-1169.